AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (currently amended). A compound of formula (I):



(I)

in which A is a C alkylene group with a chain length between NH and N(O)R'R" of at least 2 carbon atoms and R' and R" are each separately selected from C_{1-4} alkyl groups and C_{2-4} hydroxyalkyl and C_{2-4} dihydroxyalkyl groups in which the carbon atom attached to the nitrogen atom does not carry a hydroxy group and no carbon atom is substituted by two hydroxy groups, or R' and R" together are a C_{2-6} alkylene group which with the nitrogen atom to which R' and R" are attached forms a heterocyclic group having 3 to 7 atoms in the ring, ~~characterised in that~~ wherein the compound is formulated so that upon dissolution in aqueous solution the pH of the solution is in the range of 5 to 9.

2 (currently amended). A compound as claimed in claim 1 ~~characterised in that~~ wherein the compound is formulated so that upon dissolution in aqueous solution the pH of the solution is in the range of 6 to 8.

3 (currently amended). A compound as claimed in claim 1 ~~characterised in that~~ wherein the compound is used in the form of a salt with an physiologically acceptable acid having a pK_a in the range of –3.0 (minus 3.0) to 9.0.

4 (currently amended). A compound of formula (I):



(I)

in which A is a C alkylene group with a chain length between NH and N(O)R'R" of at least 2 carbon atoms and R' and R" are each separately selected from C_{1-4} alkyl groups and C_{2-4} hydroxyalkyl and C_{2-4} dihydroxyalkyl groups in which the carbon atom attached to the nitrogen atom does not carry a hydroxy group and no carbon atom is substituted by two hydroxy groups, or R' and R" together are a C_{2-6} alkylene group which with the nitrogen atom to which R' and R" are attached forms a heterocyclic group having 3 to 7 atoms in the ring,

~~characterised in that~~ wherein the compound is in the form of a salt with a physiologically acceptable acid having a pK_a in the range of –3.0 (minus 3.0) to 9.0.

5 (currently amended). A compound as claimed in claim 3 ~~characterised in that~~ or claim 4, wherein the physiologically acceptable acid has a pK_a in the range of 2.0 to 9.0.

6 (currently amended). A compound as claimed in claim 5 ~~characterised in that~~ wherein the physiologically acceptable acid has a pK_a in the range of 2.0 to 6.0.

7 (currently amended). A compound as claimed in claim 6 ~~characterised in that~~ wherein the physiologically acceptable acid has a pK_a in the range of 3.0 to 6.0.

8 (currently amended). A compound as claimed in claim 3 ~~characterised in that~~ wherein the physiologically acceptable acid is an organic mono- , di- or tri-acid.

9 (currently amended). A compound as claimed in claim 3 ~~characterised in that~~ or claim 4, wherein the physiologically acceptable acid is selected from the group consisting of tartaric acid, malonic acid, dichloroacetate acid, citric acid, maleic acid, benzenesulfonic acid, pimelic acid and acetic acid.

10 (currently amended). A compound as claimed in claim 1 ~~characterised in that~~ or claim 4, wherein A is a straight chain alkylene group.

11 (currently amended). A compound as claimed in claim 1 ~~characterised in that~~ or claim 4, wherein A is ethylene.

12 (currently amended). A compound as claimed in claim 1 ~~characterised in that~~ or claim 4, wherein R' and R" are straight chain alkyl groups or hydroxy-substituted alkyl groups.

13 (currently amended). A compound as claimed in claim 12 ~~characterised in that~~ wherein R' and R" are each CH_3 or CH_2CH_3.

14 (currently amended). A compound as claimed in claim 13 ~~characterised in that~~ wherein each group of formula NH–A–N(O)R'R" is group of formula NH–$(CH_2)_2$–$N(O)(CH_3)_2$.

15 (currently amended). A compound as claimed in claim 1 ~~characterised in that~~ or claim 4, wherein the compound is formulated in a mixture containing additional components so that upon dissolution in aqueous solution the pH of the solution is buffered to be in the range of 5 to 9.

16 (currently amended). An aqueous solution of a compound as claimed in claim 1, ~~characterised in that~~ or claim 4, wherein the pH of the solution is in the range of 5 to 9.

17 (currently amended). A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or claim 4, together with a physiologically acceptable diluent or carrier.

18 (canceled).

19 (new). Method of treating cancer in a warm blooded animal comprising administering to said animal an effective amount of a compound of formula (I) as claimed in claim 1 or claim 4, wherein said cancer is selected from the group consisting of breast cancer, lung cancer, prostate cancer, pancreatic cancer, oesophageal cancer, non-Hodgkin's lymphoma and acute non-lymphocytic leukaemia.